钠–葡萄糖协同转运蛋白2（SGLT2）抑制剂是近年来应用于临床的新型口服抗糖尿病药物，主要通过抑制分布在肾脏肾小管处的SGLT2来阻止多余葡萄糖的重吸收，促进尿糖排泄，从而降低循环血糖水平，同时发挥利钠、利尿作用，对充血性心力衰竭也是一种新的治疗选择。随着越来越多的人群受用，研究发现SGLT2抑制剂还具有降低心血管结局等多种心血管保护作用，不仅可使心衰患者受益，对心肌梗死也呈现出多效性，尽管相关机制目前只是推测。主要对SGLT2抑制剂治疗心肌梗死的相关研究进行综述。

The sodium-glucose cotransporter 2 (SGLT2) inhibitor is a new type of oral antidiabetic drug, which has been used in clinic in recent years. It mainly prevents the reabsorption of excess glucose by inhibiting SGLT2 distributed in renal tubules, promotes the excretion of urine glucose, so as to reduce the level of circulating blood glucose, and plays the role of natriuretic and diuretic. It is also a new treatment option for congestive heart failure. With more and more people using SGLT2 inhibitors, it has been found that SGLT2 inhibitors can also reduce cardiovascular outcomes and other cardiovascular protective effects, which can not only benefit the patients with heart failure, but also have multiple effects on myocardial infarction. Although the relevant mechanism is only speculated at present, the potential of SGLT2 inhibitors in the treatment of myocardial infarction is ready to come out. The research progress on effect of sodium - glucose co-transporter 2 inhibitors on myocardial infarction is reviewed in this paper.

R972